200 related articles for article (PubMed ID: 8458110)
1. Dose-ranging study with a new two-chain rt-PA in patients with acute myocardial infarction: a multicenter trial.
DeWood MA; Kurnik PB; Jolly MK; Jain AC; Khaja F; Gorfinkel HJ; Morris DL; Satler L; LittleJohn J
Clin Cardiol; 1993 Apr; 16(4):302-10. PubMed ID: 8458110
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a prolonged infusion of recombinant tissue-type plasminogen activator (Duteplase) in preventing reocclusion following successful thrombolysis in acute myocardial infarction.
Kalbfleisch J; Thadani U; LittleJohn JK; Brown G; Magorien R; Kutcher M; Taylor G; Maddox WT; Campbell WB; Perry J
Am J Cardiol; 1992 May; 69(14):1120-7. PubMed ID: 1575179
[TBL] [Abstract][Full Text] [Related]
3. Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA.
Arnold AE; Brower RW; Collen D; van Es GA; Lubsen J; Serruys PW; Simoons ML; Verstraete M
J Am Coll Cardiol; 1989 Sep; 14(3):581-8. PubMed ID: 2504798
[TBL] [Abstract][Full Text] [Related]
4. Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction.
Gulba DC; Tanswell P; Dechend R; Sosada M; Weis A; Waigand J; Uhlich F; Hauck S; Jost S; Rafflenbeul W; Lichtlen PR; Dietz R
J Am Coll Cardiol; 1997 Dec; 30(7):1611-7. PubMed ID: 9385884
[TBL] [Abstract][Full Text] [Related]
5. Myocardial infarct artery patency and reocclusion rates after treatment with duteplase at the dose used in the International Study of Infarct Survival-3. Burroughs Wellcome Study Group.
Kalbfleisch JM; Kurnik PB; Thadani U; DeWood MA; Kent R; Magorien RD; Jain AC; Spaccavento LJ; Morris DL; Taylor GJ
Am J Cardiol; 1993 Feb; 71(5):386-92. PubMed ID: 8430624
[TBL] [Abstract][Full Text] [Related]
6. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS).
Neuhaus KL; von Essen R; Tebbe U; Vogt A; Roth M; Riess M; Niederer W; Forycki F; Wirtzfeld A; Maeurer W
J Am Coll Cardiol; 1992 Apr; 19(5):885-91. PubMed ID: 1552106
[TBL] [Abstract][Full Text] [Related]
7. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
Zarich SW; Kowalchuk GJ; Weaver WD; Loscalzo J; Sassower M; Manzo K; Byrnes C; Muller JE; Gurewich V
J Am Coll Cardiol; 1995 Aug; 26(2):374-9. PubMed ID: 7608437
[TBL] [Abstract][Full Text] [Related]
8. Patency trials with reteplase (r-PA): what do they tell us?
Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W
Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406
[TBL] [Abstract][Full Text] [Related]
9. ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction.
Malcolm AD; Keltai M; Walsh MJ
Eur Heart J; 1996 Oct; 17(10):1522-31. PubMed ID: 8909909
[TBL] [Abstract][Full Text] [Related]
10. Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study Group.
Wall TC; Califf RM; George BS; Ellis SG; Samaha JK; Kereiakes DJ; Worley SJ; Sigmon K; Topol EJ
J Am Coll Cardiol; 1992 Mar; 19(3):482-9. PubMed ID: 1537998
[TBL] [Abstract][Full Text] [Related]
11. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).
Arnout J; Simoons M; de Bono D; Rapold HJ; Collen D; Verstraete M
J Am Coll Cardiol; 1992 Sep; 20(3):513-9. PubMed ID: 1512327
[TBL] [Abstract][Full Text] [Related]
12. Enhanced myocardial salvage by maintenance of microvascular patency following initial thrombolysis with recombinant tissue plasminogen activator.
Longridge DJ; Follenfant MJ; Maxwell MP; Ford AJ; Hughes B
Cardiovasc Res; 1990 Sep; 24(9):697-706. PubMed ID: 2121357
[TBL] [Abstract][Full Text] [Related]
13. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial.
Brener SJ; Zeymer U; Adgey AA; Vrobel TR; Ellis SG; Neuhaus KL; Juran N; Ivanc TB; Ohman EM; Strony J; Kitt M; Topol EJ
J Am Coll Cardiol; 2002 Feb; 39(3):377-86. PubMed ID: 11823073
[TBL] [Abstract][Full Text] [Related]
14. HBW 023 (recombinant hirudin) for the acceleration of thrombolysis and prevention of coronary reocclusion in acute myocardial infarction: results of a dose-finding study (HIT-II) by the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte.
von Essen R; Zeymer U; Tebbe U; Jessel A; Kwasny H; Mateblowski M; Niederer W; Wagner J; Mäurer W; von Leitner ER; Haerten K; Roth M; Neuhaus KL
Coron Artery Dis; 1998; 9(5):265-72. PubMed ID: 9710686
[TBL] [Abstract][Full Text] [Related]
15. Dose-related efficacy and bleeding complications of double-chain tissue plasminogen activator in acute myocardial infarction. The Wellcome Tissue Plasminogen Activator Study Group.
Turi ZG; Goldberg S; LittleJohn JK; Vander Ark C; Shadoff N; Karlsberg R; Williams J; Butman S; Stadius ML; Wise K
Am J Cardiol; 1993 May; 71(12):1009-14. PubMed ID: 8475860
[TBL] [Abstract][Full Text] [Related]
16. A randomized dose-ranging study of rt-PA in acute myocardial infarction. Effects on coronary patency and fibrinolytic parameters.
Koster RW; van Stralen R; McNeill AJ; Adgey AA; Fox KA; Dymond D; Sponzilli C; Jewitt D; Bucknall C; Kluft C
Eur Heart J; 1990 Aug; 11(8):730-9. PubMed ID: 2118853
[TBL] [Abstract][Full Text] [Related]
17. Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study Group.
Kirshenbaum JM; Bahr RD; Flaherty JT; Gurewich V; Levine HJ; Loscalzo J; Schumacher RR; Topol EJ; Wahr DW; Braunwald E
Am J Cardiol; 1991 Dec; 68(17):1564-9. PubMed ID: 1746455
[TBL] [Abstract][Full Text] [Related]
18. Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group.
Topol EJ; Ellis SG; Califf RM; George BS; Stump DC; Bates ER; Nabel EG; Walton JA; Candela RJ; Lee KL
J Am Coll Cardiol; 1989 Oct; 14(4):877-84. PubMed ID: 2477426
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group.
Vanderschueren S; Barrios L; Kerdsinchai P; Van den Heuvel P; Hermans L; Vrolix M; De Man F; Benit E; Muyldermans L; Collen D
Circulation; 1995 Oct; 92(8):2044-9. PubMed ID: 7554180
[TBL] [Abstract][Full Text] [Related]
20. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
Bovill EG; Terrin ML; Stump DC; Berke AD; Frederick M; Collen D; Feit F; Gore JM; Hillis LD; Lambrew CT
Ann Intern Med; 1991 Aug; 115(4):256-65. PubMed ID: 1906692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]